The Business Cocktail

The Business Cocktail

Aug 02, 2016

  • Juno Therapeutics recently acquired Redox Therapies and it’s vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist. The upfront consideration for the Redox Therapies acquisition was $10 million in cash.
  • UK-based Cell Medica expands its T cell immunotherapy program with the acquisition of privately-held Delenex Therapeutics
  • Evelo Biosciences, US based Microbiome Company working in oncology through characterization of cancer associated bacteria, and Epiva Biosciences, another microbiome company from Flagship VentureLabs, merged to create a leading immuno-microbiome platform company in the U.S.
  • Medivation Inc., an American biopharmaceutical company working for the development of novel therapeutics, enters confidentiality agreement with French Drugmaker, Sanofi, who agreed to terminate its consent solicitation.
  • AstraZeneca is considering $10 billion bid for Medivation Inc., an American biopharmaceutical company, according to reports, however no formal offers have been made.
  • Evelo Biosciences, a pioneer in Oncobiotics, and Mayo Clinic, U.S.A. entered into an exclusive research collaboration for Immuno-microbiome Cancer Therapies, for advance development of cancer-associated bacteria library, a key platform discovery tool of the former for the development of onco-microbials to treat cancer.

Downloads

Article in PDF

Recent Articles
medtech-news-for-medtronic-roche-boston-scientific
Notizia - Recent Pharma, Healthcare and Biotech Happenings

May 01, 2025

Medtronic Receives FDA Approval for OmniaSecure™ Lumenless Defibrillation Lead and Presents Positive Clinical Trial Results for Hugo™ Robotic-Assisted Surgery System; Roche’s AI Companion Diagnostic for NSCLC Earns FDA Breakthrough Device Designation; Boston Scientific Announces Positive 12-Month Phase 2 Results from ADVANTAGE AF Trial of FARAPULSE™ PFA System; Bausch Health Launches Fraxel FTX™ to Advance Skin Rejuvenation Treatments; Gestalt Diagnostics Secures $7.5M in Series A to Scale AI Pathology Solutions

us-tariffs-2025-impact-healthcare-pharma-strategies
Articles

Apr 30, 2025

Navigating U.S. Tariffs in 2025: Impacts and Strategies for Pharma and Healthcare

pharma-news-for-boston-scientific-roche-northstrive
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Apr 29, 2025

Boston Scientific Pushes Forward Despite $200M Tariff Challenge; Northstrive Biosciences Gets FDA Green Light to Advance EL-22 Obesity Trial; Roche Acts Swiftly to Offset U.S. Tariff Impact with Global Engagements; Verastem Oncology Secures IND Clearance for KRAS G12D Inhibitor Trial; BlackfinBio Gets FDA OK for Phase I/II Trial of BFB-101 in SPG47

Cancer
Colorectal Cancer
DelveInsight
FDA
Latest pharma news
news
Non-small cell lung cancer
obesity
obesity drugs
Obesity Market
obesity pipeline
Pancreatic Cancer
pharma news
recent pharma news
tariff
loader